By: DengYue International Business DivisionTen years ago, China was known primarily as a supplier of APIs and low-cost generic medicines to the world. Today, if someone tells you that China is developing, manufacturing, and exporting world-class oncology drugs, biologics, ...Learn More

In the realm of biotechnology and molecular biology, the integrity of pharmaceuticals is paramount, directly impacting research outcomes, clinical trials, and public health. While China's regulatory framework for drugs has advanced significantly, counterfeit ...Learn More

By DengYueMed International Business DivisionToday, DengYueMed shares key commercial insights into China’s EGFR small-molecule targeted therapy market with international buyers and distribution partners. Drawing on the latest publicly available data, we analyzed the sales trends ...Learn More

As the global pharmaceutical industry transitions into a new era of innovation and precision medicine, the significance of Formulation Development has become increasingly prominent. It not only relates to the safety, efficacy, and stability of drugs but also serves as the critical ...Learn More

As November 2025 arrives, the global pharmaceutical industry stands at a pivotal moment.In October alone, China saw six innovative drugs approved for market launch, including the world’s first EGFR-targeting Antibody–Drug Conjugate (ADC), Becotatugvedotin for Injection.This ...Learn More